PROMETHEUS® Celiac Serology
Cat. # 1155

Test Description

PROMETHEUS® Celiac Serology is a comprehensive serum antibody profile. By combining important serologic markers for diagnosing celiac disease and utilizing a 5-marker panel including deamidated gliadin peptides, EMA-IgA and tTG-IgA, this test offers reliable and consistent results from a recognized leader in celiac testing. Knowledge of serologic markers may help detect celiac disease by providing serologic answers.

- An evaluation of antibodies associated with celiac disease to assist physicians with diagnosis and dietary compliance.
- **Specimen Requirements** - Serum, 2.0 mL (SST or Red Top Tube)
- **Shipping and Handling** - Ambient or cold pack
- **Storage Conditions/Stability** - 7 days room temp; 30 days refrigerated
- **Turn Around Time** - 2-3 business days from date of receipt
- **Reference Range:**
  - Deamidated gliadin peptide antibody IgG ELISA: <4.9 EU/mL
  - Deamidated gliadin peptide antibody IgA ELISA: <6.1 EU/mL
  - Anti-human tTG IgA ELISA: <10.3 U/mL
  - Anti-endomysial IgA IFA: Negative
  - Total serum IgA: < 3 years: 8-220 mg/dL; 3-13 years: 41-395 mg/dL; >13 years: 44-441 mg/dL

Facilities Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. Prometheus Laboratories Inc. is a CAP-accredited CLIA laboratory.

CPT Codes (as applied by Prometheus)

- **83520(X3), ELISA; antibody specific** (Deamidated gliadin peptide IgA, Deamidated gliadin peptide IgG, anti-tissue transglutaminase IgA)
- **88347**, Anti-endomysial (EMA) IgA antibody by IFA
- **82784**, Total serum IgA, by nephelometry

Literature References

- Mothes, T., Deamidated Gliadin Peptides as Targets for Celiac Disease-Specific Antibodies; *Advances in Clinical Chem,* 2007; Vol. 44, 35-63.